J. Lyle Bootman, PhD, ScD
Dean, College of Pharmacy
Professor: Pharmacy, Medicine, Public Health
Founding Executive Director, Center for Health Outcomes & PharmacoEconomic Research
College of Pharmacy Administration
Dr. Bootman has served as dean of the UA College of Pharmacy since 1987. He is professor of pharmacy, medicine and public health, and a fellow of several professional associations, including the American Pharmacists Association, American Association of Pharmaceutical Scientists and the American College of Apothecaries. He is the founding and executive director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research, one of the first such centers developed in the world. He is also a founding director of the Healthcare Transformation Institute (HTI), the first company launched to truly advance our country’s healthcare system by developing new delivery models in improving patient healthcare value, patient outcomes and services.
He received his pharmacy education at the University of Arizona and his doctorate at the University of Minnesota, where he was given the Outstanding Achievement Award, the university’s highest alumni honor. He completed a clinical pharmacy residency at the world-renowned National Institutes of Health.
Dr. Bootman has authored more than 285 research articles, books and monographs, and has been an invited speaker at more than 600 professional healthcare meetings and symposia. He has received numerous outstanding scientific achievement awards, most notably from the American Association of Pharmaceutical Scientists and the Academy of Pharmaceutical Science and Research for his research, which pioneered the field of pharmacoeconomics and health outcomes. He has published several books including the first textbook introducing the principles of pharmacoeconomics, which is utilized in more than 40 countries and translated in seven languages. His research regarding the outcomes of drug-related morbidity and mortality receives worldwide attention by the professional and the public media.
Additionally, he is an elected member of the Institute of Medicine of the National Academies, where he served on the Board of Health Care Services for seven years, and was co-chair of the IOM committee which released the highly publicized report “Preventing Medication Errors.” He serves as an adviser to leading pharmaceutical companies, universities and healthcare organizations throughout the world. Currently, he serves on several prestigious boards, including HTI, The Critical Path Institute, Research Corporation Technologies, CMR Institute and Madeira Therapeutics.
Dr. Bootman has been lauded with numerous honors and awards recognizing him for his outstanding lifetime contributions and service to the profession and to society.
University of Arizona, College of Pharmacy, BS, 1974, Pharmacy
University of Minnesota, MS, 1976, Pharmacy Administration
University of Minnesota, PhD, 1978, Pharmacy Administration
Honors and Awards (selection)
1997 George F. Archambault Award, American Society of Consultant Pharmacists
1997 One of the 50 Most Influential Pharmacists in America, selected by the American Druggist
1998 Elected President of the American Pharmaceutical Association
1998 The University of Minnesota Board of Regents Outstanding Achievement Award
1998 Elected to the Institute of Medicine of the National Academies
2000 Latiolais Honor Medal, Pharmaceutical Care Management Association
2003-2006 President, Pharmacy & Therapeutics Society
2007 Hugo H. Schaefer Award, American Pharmacists Association
2008 Remington Honor Medal, American Pharmacists Association
2011 Elected President of the American Association Colleges of Pharmacy
Bootman JL, Nash D. Advanced Concepts in Managed Healthcare: Role of the Pharmaceutical Industry in Integrated Healthcare Systems. J. Pharm. Rep. 1995; 25(8):4-7.
Johnson J, Bootman JL. Drug Related Morbidity and Mortality: A Cost of Illness Model. Archives of Internal Medicine 1995; 155: Oct. 9;1949-1956.
Bootman JL. Pharmacoeconomics and Outcomes Research. American Journal of Health-System Pharmacy July 15, 1995; 52 (3):6-19.
Bootman JL. Pharmacoeconomics: An Emerging Discipline for the Pharmacy Profession. Pharmacy World and Science 1996; 18 (1):3-4.
Bootman JL. Milne R, Costs, Innovation and Efficiency in Anti-infective Therapy, PharmacoEconomics 1996; 9(Suppl-1):31-39.
Bootman JL. The $76 Billion Wake-up Call, Journal of the American Pharmacists Association 1996; NS36(1):27-28.
Bootman JL. Pharmacoeconomics and Therapeutic Drug Monitoring, Marketing for Health 1996; 6(2):10-12.
Gouveia WA, Bootman JL. The Outcomes Movement of Its Influence as the Future of Pharmacy Practice and Research. Actes DV XXXII Congress Internationale D’Historie De La Pharmacie Proceedings, Paris, France 1996; (2):256-288.
Johnson J, Bootman JL. Drug Related Morbidity and Mortality and the Economic Impact of Pharmaceutical Care. American Journal of Health Systems Pharmacy March 1, 1997; 54:554-558.
Bootman JL, Harrison D. Pharmacoeconomics of Therapeutic Drug Monitoring. Pharmacy World and Science 1997; 19(3):1-4.
Bootman JL, and Langley P. Pharmacoeconomics, Prescribing and Reimbursement of Pharmaceuticals. Journal of Applied Therapeutics 1997; 1(1):275-283.
Bootman JL, Piech C. Cost Effectiveness of Two New Treatments for Onychomycosis: An Analysis of Two Comparative Clinical Trials. Journal of the American Academy of Dermatology 1998; 28: S69-72.
Bootman JL. The Impact of Pharmacoeconomic Data. Pharmaceutical Representative
Grudzinski A, Hakim Z, Cox E, Bootman JL. The Economics of Multiple Sclerosis; Distribution of Costs and Relationship to Disease Severity. Pharmacoeconomics 1999; 15(3):229-240.
Bootman JL. Coming Full Circle – Bridging the Gaps to Quality Patient Care in the New Millennium. Journal of the American Pharmacists Association 1999 July/Aug; 39(4):6-8.
Grudzinski A, Hakim Z, Cox E, Bootman JL. Economic Assessment of the Relationship Between Disease Exacerbations and the Cost of Multiple Sclerosis. Journal of Managed Care Pharmacy
2000 January/February; 6(1):19-24.
Bootman JL. Letter From the Editors: A Singleness of Purpose-Aspectrum of Expertise and Care-What Will the Future Bring?. Oncology Spectrums 2001; 2(1):16 (Formerly One-Oncology Economics)
Bootman JL. Balancing Outcomes for the 21st Century. Journal of Managed Pharmaceutical Care 2001; 1(1):19-22.
Zachry, WM, Bootman JL. The Role of the Pharmacist in Reducing Preventable Adverse Drug Events. P&T Journal 2001; 26(8):436-440.
Bootman JL, Von Hoff DD. Letter From the Editors: T-minus 10 Years and Counting. Oncology Spectrums 2002; 3(1):9.
Bootman JL. Drug-Related Morbidity and Mortality: An Economic and Clinical Perspective. Managed Care 2002; 11(2):12-15.
Johnson, J, Bootman, JL, Evans WE, et al. Pharmacogenomics: A Scientific Revolution in Pharmaceutical Sciences and Pharmacy Practice. American Journal of Pharmaceutical Education 2002; 86(Winter Supplement):1-8.
Bootman JL, Eichler AG, Jönsonn B, Moerman DL, Poste G, Kielgast P, Hoek T, Sousa-Pinto G. International Forum on Medicines: Presentation of the Forum and Current Agenda Areas. Federation of International Pharmacy 2003; 1:1-30.
Eichler AG, Bootman JL, Jönsonn B, Moerman DL, Poste G. International Forum on Medicines: The Need to Assess the Value of Medicines. Federation of International Pharmacy 2003; 2:1-30.
Bootman JL, Eichler AG, Jönsonn B, Moerman DL, Poste G. International Forum on Medicines: Achieving the Value of Medicines. Federation of International Pharmacy 2003; 3:1-30.
Praznovcova L, Bootman JL. Pharmacoeconomics of Hypertension. MediNEWS 2003; 6/7:31-36.
Bootman JL, Crown WH, Luskin, AT. Clinical and Economic Effects of Suboptimally Controlled Asthma. Managed Care Interface 2004; 17(1):31-36.
Bootman JL. A Major Milestone of the Pharmacy & Therapeutics Society. Managed Care Interface 2005; 18(10):16.
Bootman JL, McGhan WF, Townsend RJ. Pharmacoeconomics: Historical Perspective. Annals of Pharmacotherapy 2006; 40(3).
Bootman JL. Honor Bound to Lead. Journal of the American Pharmacists Association 2008; 48 (4):464-469.
Bootman JL, Skrepnek GH. Achieving value: the role of pharmacoeconomics. Pharmaceutical Policy and Law | IOS Press; 2012: 14(1):3-6.
Abraham I., Bootman JL. Why pharmacoeconomic policy should be transnational. Pharmaceutical Policy and Law | IOS Press 2012: 14(1):7-16.
Bootman JL. Transforming Healthcare, American Journal for Pharmaceutical Education, Editorial Board 2012; 76(7):122.